Classical Hodgkin Lymphoma: Answers to the Important Management Questions in 2021

Abstract Classical Hodgkin lymphoma (HL) is often cured with frontline therapy; however, up to 15–25% patients with advanced stage and up to 10% with early stage need additional treatment. When second-line therapy is required, up to 2/3 of patients are cured with a consolidative autologous stem cell transplant (ASCT). If this treatment fails, patients can still live for many years on chronic therapy. Many questions are still relevant in the management of HL, however. The ones most important in 2021 are as follows: 1) Are there any patients in CR who require consolidative radiotherapy? 2) Is BV-AVD the standard therapy for ASHL? 3) Which patients should receive maintenance therapy after ASCT? 4) Is there any hope for patients when checkpoint inhibitors (CPI) fail?